CONSENSO SBU-SP - Sobre o tratamento do Câncer de Urotélio
Proeminentes nomes prepararão importante Consenso e apresentarão os resultados finais. Dia 03/11 das 12h00 às 13h30. PARTICIPE
Maria De Santis is a medical oncologist and Chair of Section for Interdisciplinary Genito-Urinary Cancer Medicine at the Charité Medical University Hospital, Berlin, Germany. She has been Associate Professor of Medicine at Paracelsus Medizinische Privatuniversität in Salzburg, Austria, since 2008, and working as a senior consultant at the 3rd Medical Department – Center of Oncology and Hematology at Kaiser Franz Josef-Spital in Vienna for 18 years, where she has also lead the Genito-Urinary Oncology Service for 11 years. From 2015 until April 2018 she was appointed Associate Clinical Professor for Oncology at the University of Warwick, Coventry, and working clinically in genitourinary oncology at the Queen Elizabeth Hospital, Cancer Center, in Birmingham, UK.
Also, she has been appointed Adjunct Professor at the Department of Urology at the Medical University of Vienna, Austria, in 2016. Dr De Santis is a member of several international scientific committees, including the European Society of Medical Oncology, the European Association of Urology and the European Organization for Research and Treatment of Cancer.
She also served as a scientific committee member of the American Society of Clinical Oncology for a 3 year term. She has authored multiple peer-reviewed articles in genito-urinary cancer medicine. In addition, Dr De Santis is a panel member of the European Association of Urology (EAU) Scientific Office and the EAU Prostate Cancer guidelines panel. Her main research interests include prostate and bladder cancer.
Area of Excellence: Clinical Expertise and Innovation
The focus of my clinical and research endeavors is optimizing the treatment of men with aggressive, high-risk prostate cancer through a busy clinical practice (60% effort), research (20% effort), and teaching (10% effort). I also spend a significant amount of time on administrative leadership (10% effort) as vice-chair for clinical research, and co-leader of the DF/BWCC Genitourinary disease center.
My research program primarily seeks to identify clinical and genomic prognostic factors to optimize the therapeutic ratio for men with high-risk prostate cancer through judicious use of androgen deprivation therapy (ADT) with radiation. My secondary research focus is optimizing the delivery of care for men with aggressive prostate cancer through health services research...
Quoc-Dien Trinh, MD is an Assistant Professor of Surgery at Harvard Medical School, Brigham and Women’s Hospital and Dana-Farber Cancer Institute. He is the Co-Director of the Dana-Farber/Brigham and Women’s Prostate Cancer Program and the core leader for ‘Cancer and Effectiveness’ at the Center for Surgery and Public Health, a joint program of Harvard Medical School and the Harvard School of Public Health. Dr. Trinh’s research focuses primarily on costs and patterns of health care delivery including genitourinary malignancies. His research is funded by the Vattikuti Urology Institute, the Prostate Cancer Foundation, the American Society of Clinical Oncology and the National Institutes of Health. He currently serves as the Associate Editor for health services research at the British Journal of Urology (BJU) International and Assistant Online Content Editor for the Journal of Urology. Dr. Trinh received his medical degree from the Université de Montréal in Montreal, Canada, where he also completed his residency training in Urology. He completed his fellowship in minimally invasive urologic oncology at the Vattikuti Urology Institute in Detroit, Michigan.
Is the Investigator In-Chief for the Urological Research Network Corp in Miami. A former Professor of Urology at George Washington University (Washington DC), and Columbia University (New York, NY). In South Florida currently serves as Professor of Urology for Nova Southeastern University.
An Innovator Urological Oncologist and Robotic Surgeon who has conducted more than 12 randomized clinical trials - committed to the best care options for his patients.
Dr Bianco serves as principal investigator for the Fusion Image - MRI/US -Guided Cryotherapy of the Prostate Clinical Trial - NCT02381990 – an innovative disruptive technology of the FocalyxTx paradigm.
Importantly, he has been a pioneer in Urological Robotic Procedures for cancer patients and also in complex robotic reconstructive procedures and in 2015 was the lead author of the first Level 1 evidence study - NCT01371994 - that evaluated Urinary Continence Outcomes after Robotic Prostatectomy published in the Journal of Urology.
In addition, Dr. Bianco has served as a lead scientist involved in the PRO-IMPACT trial that evaluates the molecular profiles of prostate cancers and its chances of disseminating in the short term. This represents an important effort supported by the Society of Urological Oncology Clinical Trials Consortium NCT02080689.